Market Overview

UPDATE: Jefferies Downgrades Optimer Pharmaceuticals Following CBST Sale Announcement


In a report published Wednesday, Jefferies analyst Eun K. Yang downgraded Optimer Pharmaceuticals (NASDAQ: OPTR) from Buy to Hold, and lowered the price target from $17.00 to $13.25.

In the report, Jefferies noted, “Given anticipated OPTR take-out (speculated by CBST), this is not surprising. However, the deal price is lower than we'd anticipated # cash upfront of $10.75 ($10.72 prior to OPTR announcement for strategic review process on 2/27/13) & up to $5 CVR in 2016 on Dificid sales. On strong 2Q13 sales, OPTR is confident of achieving $5 CVR (ultimate takeout value of $15.75); our conservative Dificid sales estimates puts $3 CVR ($13.75/sh).”

Optimer Pharmaceuticals closed on Tuesday at $13.29.

Latest Ratings for OPTR

Jul 2013DowngradesBuyHold
Jul 2013DowngradesBuyHold
May 2013DowngradesOutperformNeutral

View More Analyst Ratings for OPTR
View the Latest Analyst Ratings

Posted-In: Eun K. Yang JefferiesAnalyst Color Downgrades Analyst Ratings


Related Articles (OPTR)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Benzinga's Top Initiations

UPDATE: J.P. Morgan Upgrades Compass Minerals on Valuation